A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy
1505-0001
Phase 1 other active
Quick answer
A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy for Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- Metastatic pancreatic ductal adenocarcinoma (mPDAC)
- Phase
- Phase 1
- Modality
- other
- Status
- active